Across TCGA pan-cancer cohorts, PGGT1BP2 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of PGGT1BP2’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where PGGT1BP2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PGGT1BP2 is over-expressed in tumor, although a few such as KIRP and KICH show the opposite, repressed pattern.

LUAD, KIRP, and KICH are the cancer types where PGGT1BP2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PGGT1BP2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	All	+0.220	<.001	8	view →
KIRP	Female	All	−0.070	.002	2	view →
KICH	Male	All	−0.038	.030	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: PGGT1BP2 RNA expression & survival · all PGGT1BP2 data types